Memory Improvement Through Nicotine Dosing (MIND) Study
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if daily transdermal nicotine is able to produce a
significant cognitive, clinical and functional improvement in participants with MCI. Neuronal
nicotinic receptors have long been known to play a critical role in memory function in
preclinical studies, with nicotine improving attention, learning, and memory function.
The study will enroll 300 participants for a 2 year period. Participants will be randomized
(50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day,
or placebo skin patch.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
Alzheimer's Therapeutic Research Institute National Institute on Aging (NIA) Vanderbilt University Vanderbilt University Medical Center